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ABSTRACT 
Colorectal cancer (CRC) is a major cause of cancer-associated deaths worldwide.  Recently, oral 
administration of resveratrol (trans-3,5,4’-trihydroxystilbene), has been reported to significantly 
reduce tumor proliferation in colorectal cancer patients, however, with little specific information 
on functional connections. The pathogenesis and development of colorectal cancer is a multi-step 
process that can be categorized using three phenotypic pathways, respectively, chromosome 
instability (CIN), microsatellite instability (MSI) and CpG island methylator (CIMP).  Targets of 
resveratrol, including a high affinity binding protein, quinone reductase 2 (QR2), have been 
identified with little information on disease association. We hypothesize that the relationship 
between resveratrol and different CRC etiologies might be gleaned using publicly available 
databases. A web-based microarray gene expression data-mining platform, Oncomine, was 
selected and used to determine whether QR2 may serve as a mechanistic and functional biotarget 
within the various CRC etiologies. We found that QR2 mRNA is overexpressed in CRC 
characterized by CIN, particularly in cells showing a positive KRAS (Kirsten rat sarcoma viral 
oncogene homolog) mutation, as well as by the MSI but not the CIMP phenotype. Mining of 
Oncomine revealed an excellent correlation between QR2 mRNA expression and certain CRC 
etiologies. Two resveratrol associated genes, adenomatous polyposis coli (APC) and TP53 found 
in CRC were further mined, using cBio portal and Colorectal Cancer Atlas which predicted a 
mechanistic link to exist between resveratrol→QR2/TP53→CIN.  
Multiple web-based data mining can provide valuable insights which may lead to hypotheses 
serving to guide clinical trials and design of therapies for enhanced disease prognosis and patient 
survival.  This approach resembles a BioGPS, a capability for mining Web-based databases that 
can elucidate the potential links between compounds to provide correlations of these interactions 
with specific diseases.  
Key Words Oncomine; Colorectal Cancer Atlas; cBio Portal; Resveratrol; Colorectal 
Carcinoma (CRC); Quinone reductase 2 
 
Oncomine is a readily available web-based platform that gives insight into cancer genomics by 
providing microarray datasets for different cancers (www.oncomine.org) (Rhodes et al., 2004; 
Rhodes et al., 2007). The expression level of the QR2 gene in CRC was analyzed by searching 
the Oncomine database. The mRNA expression of QR2 in clinical samples of normal versus 
CRC patients and QR2 mRNA expression among different types of CRC were also compared.  
The cBio Cancer Genomics Portal (http://cbioportal.org) is a resource for exploring, visualizing, 
and analyzing data from multidimensional cancer genomics by reducing molecular profiles  
from cancer tissues and cell lines into understandable genetic, epigenetic, gene expression, and 
proteomic events. The query interface thus enables researchers to interactively explore genetic 
alterations across samples, genes, and pathways.  This database (Cerami et al., 2012; Gao et al., 
2013) was used to explore the connectivity of resveratrol associated genes across all CRC studies 
available in the databases.  The Colorectal Cancer Atlas database (http://www.colonatlas.org) is 
an additional open platform accessed by using categorized lists of genes, sequence variations, 
cell lines and techniques (Chisanga et al., 2016). The gene information page includes features 
such as gene details, domain details, post-translational modifications, protein identification, 
sequence variations, pathways and protein-protein interactions. We explored the Colorectal 
Cancer Atlas to interactively probe the protein-protein network of resveratrol target QR2.  
Combined with Oncomine and the cBio Cancer Genomics Portal, the Colorectal Cancer Atlas 
provided the third source for a workflow platform in categorizing molecular mechanisms of 
resveratrol and its association with clinical outcomes found in CRC.   
Resveratrol has been shown to have chemopreventive effects in CRC and its utility in adjunctive 
therapy has been supported by clinical studies  (Nguyen et al., 2009; Patel et al., 2010). We 
evaluated whether the gene of its high affinity target protein, QR2, can be used to generate 
hypotheses regarding chemopreventive efficacies of resveratrol on CRC with varying etiologies. 
The Oncomine database revealed that QR2 is correlated with CIN harboring the KRAS mutation; 
with statistically significant overexpression of QR2 mRNA occurring in KRAS-mutated 
compared to wild type KRAS carcinomas.  KRAS (12p12.1) encodes a GTP-binding protein that, 
when mutated, can cause a loss of intrinsic GTPase activity and, accordingly, elicits constitutive 
signaling through the RAS-RAF-MEK-ERK cascade. Elevated levels of QR2 could conceivably 
increase demand for its co-substrate, N-ribosyl nicotinamide ( NRN), by enhancing hydrolysis of 
NAD+ or NADP+.  Reduction in the levels of NAD+ or NADP+ can result in an enhanced 
oxidized cellular environment.   High expression of QR2 could also result in increased cellular 
levels of oxidized NRN which can cause G1/S cell cycle arrest and inhibit inosine 5’ 
monophosphate dehydrogenase (Gharehbaghi et al., 1994), an enzyme involved in de novo GTP 
biosynthesis. It is however noteworthy that an increased production of guanine nucleotides 
occurs in rapidly proliferating cells ultimately affecting the functioning of mutated KRAS.   In 
addition, since NAD+ functions as the substrate for poly(ADP-ribose) polymerase 1 (PARP-1),  
a decrease in its level would diminish formation of poly (ADP-ribosylated) proteins that play key 
roles in several nuclear events that include DNA repair, replication, and transcription (Nakamura 
et al., 2003; Sauve, 2008).   In a broader context, however, most studies listed  (Table 1) contain 
insufficient details on the CIN pathway to CRC. This limits definitive evaluation of QR2 gene 
expression in the CIN pathway for conclusive statements or hypotheses to be reached.  The most 
pronounced QR2 changes were found in studies by Notterman et al. (2001) which showed an 
almost 400% increase in colon adenocarcinoma compared to healthy tissue. The study included 
patients from a wide age range (ages 30 to 89), from different races, early to advanced CRCs, 
male and female, and TP53 mutations (Table S1). Utilizing Oncomine to distinguish QR2 
expression for each of these subgroups, we did not find correlations among QR2 expression and 
any of these characteristics. By excluding CIMP-high patients in this study and observing that 
the CIN pathway is more commonly found in patients (Table 2), we hypothesize that these QR2 
mRNA alterations are correlated with the CIN etiology. However, the putative molecular 
determinants that underlie or contribute to the significant increase in QR2 expression in 
adenocarcinoma remain to be determined.  By contrast, as observed in the top 10% of altered 
genes, Skrzypczak et al. (2010) reported a decrease in QR2 expression in epithelial adenoma 
compared to that in normal tissue. However, the study included only females, sporadic CRC 
cases and used unpaired controls. Gender differences do not play a role in QR2 expression in 
CRC, since almost all of the studies identified in Oncomine distinguish between males and 
females, but none showed gender differences in QR2 expression. The significance of this study is 
limited, however, by small sample size (10 healthy vs. 5 adenoma) and that cancerous tissue was 
not paired with adjacent non-involved mucosa. 
The Oncomine database is available both as a subscription database and as open access. 
Although the free Oncomine version is very useful for generating general hypotheses regarding 
specific genes of interest, our analysis was limited by the paucity of gene expression data on 
QR2 and the lack of classification in several studies. To further elucidate the molecular 
mechanisms of resveratrol and its association with clinical outcomes found in CRC, cBio portal 
for Cancer Genomics (http://cbioportal.org) (Cerami et al., 2012; Gao et al., 2013) and 
Colorectal Cancer Atlas (Chisanga et al., 2016) were included with Oncomine, building on our 
recently introduced functional/activity network (FAN) analysis (Hsieh et al., 2016). Through 
systematic query of the publicly available databases, respectively, Oncomine, cBio portal and 
Colon Cancer Atlas, we propose that bioefficacy of resveratrol observed in CRC patients 
operates by the following pathway: resveratrol→QR2/TP53→CIN pathway (intersected either by 
APC↔KRAS or APC↔PIK3CA).  
This combined Oncomine-cBio Portal-Colorectal Cancer Atlas workflow platform engenders 
three simple steps: (i) identify resveratrol binding target QR2 and its association with the 
etiology of CRC using Oncomine (Rhodes et al., 2004; Rhodes et al., 2007), (ii) explore and 
verify whether genetic alterations exist for the identified resveratrol-associated genes/proteins 
across CRC samples in cancer genomics projects using cBio portal (Cerami et al., 2012; Gao et 
al., 2013) and (iii) explore Colorectal Cancer Atlas to interactively probe the protein-protein 
network of resveratrol target QR2. To our knowledge, this is a hitherto unexplored strategy that 
provides rationale as well as foundation in seeking certainty of biological plausibility. 
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